Running summarizing tools on a new article

Check the paper below, then start its synthesis.


Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease

Christian A. Ganoza (Centogene (Germany)), Ana Westenberger (University of Lübeck), Jefri J. Paul (Centogene (Germany)), Filipa Curado (Centogene (Germany)), Emma N. Somerville (Centogene (Germany)), Jörg Rennecke (Centogene (Germany)), Peter Bauer (Centogene (Germany)), Christian Beetz (Centogene (Germany))

npj Parkinson s Disease
License: CC BY-NC-ND

Abstract: We read with interest the recent studies by Skuladottir and colleagues and Cogan and colleagues, which report a novel association between monoallelic loss-of-function (LoF) variants in the ITSN1 gene and risk for Parkinson’s disease (PD) 1 , 2 . The first study observed that heterozygous LoF variants in ITSN1 confer a large risk for developing PD in analyses combining the deCODE, UK Biobank, and Accelerating Medicines Partnership Parkinson’s Disease (AMP-PD) datasets 1 . The second study identified five PD patients from three families who harbored distinct heterozygous frameshift ITSN1 variants and reported their clinical phenotype 2 . Yet another recent study reported similar results in an analysis of the UK Biobank, the AMP-PD, and the All of US cohorts, where they observed an increased risk of PD in individuals with LoF variants in ITSN1 and provided functional evidence in a Drosophila model, showing an interaction between ITSN1 – encoded Intersectin-1 and α-synuclein 3 . Still, the clinical manifestation of PD in patients with LoF variants in ITSN1 remains largely unexplored. We aimed to investigate the reported association of ITSN1 LoF variants with PD in a large independent patient group and to determine whether patients with ITSN1 LoF variants present with a clinically distinct PD form.

Published on 25 Sep. 2026